The loose mixes were collected from the field and dynamic modulus testing was conducted in the laboratory at different temperatures (i.e., 4, 21, 40, 55 °C) and frequencies (i.e., 25, 10, 5, 1, 0.5, 0.1 Hz) in accordance with AASHTO TP62.
Fractions (1 ml) were collected, mixed with 1 × protease inhibitor cocktails (Amresgo) and stored at 4°C.
Blood samples of ~0.2 ml were collected and mixed with heparin, and 100 mg of each blood sample was analysed by catalytic oxidation using Ox500 (Zinsser Analytics, Frankfurt, Germany).
Although the study is observational, data on case mix variables were collected, enabling us to control for differences in case-mix, see the results.
The RAP materials used for mix design were collected from the NH-5, Chennai-Tada section.
Data on mortality, demographic characteristics, and case-mix index were collected prospectively in the hospital core patient database and retrieved for the study.
After 20-min incubation at 37°C with mixing, cells were collected by centrifugation at 6000 g for 5 min at 4°C.
Aliquots of the thoroughly mixed urine were collected and mixed with equal volumes of Sorenson's citrate buffer (25 m m citrate buffer, pH 1.5) containing amastatin 20 μ m and stored at −70°C until analysis.
293T cells werecotransfected with lentiviral expression construct and packaging plasmids mix, and viral particles were collected after 48 hours and 72 hours.
Microbial samples were collected mixing two bottles until complete 10 l in the same spot (samples were taken in the morning after surface ice was melted) and filtered in situ with 20 µm mesh, then fixed with lugol-acetic solution (Parsons et al. 1984).
